Summary of the expert panel meeting on the role of rivaroxaban in treatment of patients with a recent acute coronary syndrome
This expert panel statement discusses the role of a new practice in prevention of cardiovascular events after an acute coronary syndrome, namely combining antiplatelet drugs with low doses a direct oral anticoagulant rivaroxaban.